



FOR HEALTH SYSTEMS & ACOs

The risk signal your quality report never sees.

The conditions you carry downside risk on surface in a dental chair months before a care manager sees them. Nesso reads that signal.

THE PROBLEM


Health systems and ACOs carry downside risk on the same chronic conditions that appear in a dental chair months before they reach a care manager. Under value-based contracts, performance is measured against a risk-adjusted benchmark, and quality thresholds gate access to shared savings entirely: **an ACO can beat its benchmark and still collect nothing.**

Undocumented conditions suppress the benchmark. Unclosed care gaps forfeit the savings. Meanwhile the periodontal findings that predict those same conditions are recorded in a dental chart no one in your population health infrastructure will ever read.

THE NESSO HEALTH SOLUTION

Nesso Health delivers the **ClarioPath™ Assessment Report**, a proprietary scoring process that converts routine periodontal findings, vitals, and a current health history into a chronic disease risk signal and treatment pathway, scored across **eight conditions**: cardiovascular disease, diabetes, kidney disease, osteoporosis, dementia, sleep apnea, pregnancy complications, and oral cancer. Treatment of the periodontal condition has been shown to improve the medical one.

WHAT THE PATIENT & CARE TEAM RECEIVES



THE EVIDENCE BASE

EVIDENCE	WHAT THE EVIDENCE SHOWS
Screening yield	20–40% of patients with periodontal disease who are screened have undiagnosed diabetes or prediabetes (EFP/IDF joint consensus, 2018).
Association base	More than 50 cohort studies covering over 4.4 million patients link periodontal disease to cardiovascular disease, stroke, and diabetes (Guo 2023, PLOS ONE; Stöhr 2021, Scientific Reports).
Umbrella review	293 systematic reviews with meta-analysis across 28 noncommunicable diseases (Botelho 2022, Nature Communications); 41 reviews and 839 primary studies on cardiovascular disease alone (Arbildo-Vega 2024).
Treatment effect: glycemic	HbA1c reduction of 0.43% at 3–4 months, moderate-certainty GRADE evidence, comparable to adding a second oral diabetes agent (Cochrane 2022; 35 RCTs, 3,249 patients).

WHAT IT IS WORTH

\$75K–\$464K

Gross annual medical cost avoided

Per 10,000 attributed lives at a 10% engagement rate, modeled from published effect sizes.

20–40%

Fewer diabetes-related ER visits

Utilization reduction is the fastest-moving lever in a shared savings contract.

\$0

Incremental medical network cost

Runs on encounters your members already have. No new sites of care, no capital build.

WHY HEALTH SYSTEMS & ACOS

Your two fastest levers are risk documentation accuracy and quality gap closure. Both depend on reaching members who are not presenting to primary care, and a dental recall visit reaches many of them.

A ClarioPath™ Assessment surfaces undocumented conditions for coding and routes members into disease management before a diagnosis triggers enrollment. Blood pressure captured chairside can contribute to Controlling High Blood Pressure. Identified and managed diabetics contribute to the glycemic control measure. Both gate shared savings, and both are scored on your annual quality report.

PARTNERSHIP MODEL

Nesso Health structures first engagements as a 90-day pilot with a defined dental practice cohort and a confirmed attribution overlap. Success criteria are agreed in advance: patients screened, percentage surfacing an undocumented condition, percentage converting to a confirmed diagnosis, all measured against your own baseline.

→

NEXT STEPS

Schedule a **30-minute discovery call** to scope a pilot against your own attributed population. Bring your attribution figures and we will size the addressable cohort together, before either of us commits to anything.